ZA951886B - Fibroblast growth factor-10 - Google Patents

Fibroblast growth factor-10

Info

Publication number
ZA951886B
ZA951886B ZA951886A ZA951886A ZA951886B ZA 951886 B ZA951886 B ZA 951886B ZA 951886 A ZA951886 A ZA 951886A ZA 951886 A ZA951886 A ZA 951886A ZA 951886 B ZA951886 B ZA 951886B
Authority
ZA
South Africa
Prior art keywords
disclosed
polypeptides
fgf
polypeptide
growth factor
Prior art date
Application number
ZA951886A
Other languages
English (en)
Inventor
Jing-Shan Hu
Jeannine D Gocayne
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of ZA951886B publication Critical patent/ZA951886B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA951886A 1994-03-08 1995-03-07 Fibroblast growth factor-10 ZA951886B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/207,412 US5817485A (en) 1994-03-08 1994-03-08 Nucleic acids and cells for recombinant production of fibroblast growth factor-10

Publications (1)

Publication Number Publication Date
ZA951886B true ZA951886B (en) 1996-09-09

Family

ID=22770445

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA951886A ZA951886B (en) 1994-03-08 1995-03-07 Fibroblast growth factor-10

Country Status (21)

Country Link
US (2) US5817485A (no)
EP (2) EP1380594A1 (no)
JP (2) JPH09510103A (no)
CN (1) CN1150804A (no)
AT (1) ATE251637T1 (no)
AU (1) AU1986195A (no)
CA (1) CA2183961A1 (no)
CZ (1) CZ260696A3 (no)
DE (1) DE69531892T2 (no)
DK (1) DK0750628T3 (no)
ES (1) ES2208676T3 (no)
FI (1) FI963475A (no)
HU (1) HUT77578A (no)
IL (1) IL112878A0 (no)
MX (1) MX9603897A (no)
NO (1) NO963728L (no)
PL (1) PL316202A1 (no)
PT (1) PT750628E (no)
SK (1) SK112996A3 (no)
WO (1) WO1995024414A1 (no)
ZA (1) ZA951886B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
EP0751992B1 (en) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US5693775A (en) * 1995-05-12 1997-12-02 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
EP0832216A4 (en) * 1995-06-05 1999-06-16 Human Genome Sciences Inc FIBROBLAST GROWTH FACTOR 15
US5773252A (en) 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
US6020189A (en) * 1996-08-30 2000-02-01 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factors (FHFs) and methods of use
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
JPH10279501A (ja) * 1997-02-10 1998-10-20 Rohto Pharmaceut Co Ltd 育毛剤
US6335317B1 (en) * 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
AU5440800A (en) * 1999-05-21 2000-12-12 Human Genome Sciences, Inc. Fibroblast growth factor 10
AU2001268427B2 (en) 2000-06-16 2007-03-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002011769A1 (en) 2000-08-04 2002-02-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
EP1385864B1 (en) 2001-04-13 2010-06-09 Human Genome Sciences, Inc. Anti-VEGF-2 antibodies
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
KR101187871B1 (ko) 2009-09-23 2012-10-05 (주)케어젠 Fgf10-유래 펩타이드 및 그의 용도
EP2643693A2 (en) * 2010-11-23 2013-10-02 KCI Licensing, Inc. Devices and methods for the diagnosis and treatment of wounds using biomarkers
CN103169658A (zh) * 2012-10-26 2013-06-26 温州医学院 成纤维细胞生长因子-10脂质体制备及在毛发再生中的应用
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 bFGFムテインおよびその製造法
AU4995193A (en) * 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells

Also Published As

Publication number Publication date
EP0750628B1 (en) 2003-10-08
FI963475A (fi) 1996-11-05
PL316202A1 (en) 1996-12-23
SK112996A3 (en) 1997-01-08
DE69531892D1 (de) 2003-11-13
DK0750628T3 (da) 2004-02-02
WO1995024414A1 (en) 1995-09-14
PT750628E (pt) 2004-03-31
CN1150804A (zh) 1997-05-28
JPH09510103A (ja) 1997-10-14
DE69531892T2 (de) 2004-07-22
NO963728L (no) 1996-11-07
IL112878A0 (en) 1995-06-29
EP1380594A1 (en) 2004-01-14
JP2002335982A (ja) 2002-11-26
US20020034787A1 (en) 2002-03-21
ES2208676T3 (es) 2004-06-16
EP0750628A4 (en) 1997-06-11
CZ260696A3 (en) 1997-05-14
AU1986195A (en) 1995-09-25
EP0750628A1 (en) 1997-01-02
CA2183961A1 (en) 1995-09-14
ATE251637T1 (de) 2003-10-15
FI963475A0 (fi) 1996-09-05
NO963728D0 (no) 1996-09-06
HUT77578A (hu) 1998-06-29
MX9603897A (es) 1997-07-31
US5817485A (en) 1998-10-06
HU9602434D0 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
ZA951886B (en) Fibroblast growth factor-10
EP0837934A4 (en) HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR 2
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
ATE430197T1 (de) Fibroblasten wachstumsfaktor-ähnliche polypeptide
ATE241639T1 (de) Keratinozyten-wachstumsfaktor 2
GR3017474T3 (en) DNA sequences, recombinant DNA molecules and processes for producing lipocortins III, IV, V & VI.
FI863626A0 (fi) Dna-sekvenser, rekombinant-dna -molekyler och foerfaranden foer framstaellning av polypeptider som liknar humant lipokortin.
ES2151557T3 (es) Corpusculos de proteinas de estaño, estanniocalcina.
EP0990000A4 (en) CONJUNCTIVE TISSUE GROWTH FACTOR 3
MX9708493A (es) Factor 15 de crecimiento de fibroblastos.
MX9706854A (es) Factor 14 de crecimiento de fibroblastos.
MX9709217A (es) Factor de crecimiento 13 de fibroblastos.
MX9707897A (es) Factor-11 del crecimiento de fibroblastos.
ATE257486T1 (de) Wachstumsfördernde proteine und peptide für epithelzellen von nieren
MX9706204A (es) Factor 2 de crecimiento de queratinocitos.
WO1999062931A3 (en) A cell density signal protein suitable for treatment of connective tissue injuries and defects
MX9709570A (es) Factor de crecimiento 3 endotelial, vascular, humano.